» Articles » PMID: 19155513

TSLP Conditions the Lung Immune Environment for the Generation of Pathogenic Innate and Antigen-specific Adaptive Immune Responses

Overview
Journal J Immunol
Date 2009 Jan 22
PMID 19155513
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

Thymic stromal lymphopoietin (TSLP) is crucial for the development of atopic diseases in humans and mice. Mice that express a lung-specific TSLP transgene (surfactant protein C promoter (SPC)-TSLP) develop a spontaneous and progressive asthma-like disease, suggesting that TSLP expression alone was sufficient for disease development. In this study, we show that, in fact, TSLP alone only causes a weak innate response that is insufficient for development of full airway inflammatory disease. Complete disease development requires both TSLP and antigenic stimulation. These data suggest that the spontaneous lung inflammation observed in SPC-TSLP mice reflects a TSLP-driven predisposition toward the development of aberrant responses against innocuous environmental Ags. This provides evidence that TSLP may act directly to induce susceptibility to the inappropriate allergic responses that characterize atopy and asthma. We additionally show that disease development requires CD4 T cells but not B cells. Further, we reveal a TSLP-driven innate response involving mucus overproduction and goblet cell metaplasia. Taken together, these data suggest a multifaceted model of TSLP-mediated airway inflammation, with an initial activation of resident innate immune cells, followed by activation of the adaptive immune system and full disease development. This study provides new insight into the unique features of the asthma pathology contributed by the innate and adaptive immune responses in response to TSLP stimulation.

Citing Articles

Association between bronchial asthma and TSLP gene polymorphism: a systematic review and meta-analysis.

Shrestha A, Pokharel P, Singh H, Shrestha S, Shrestha S, Sedhai Y Ann Med Surg (Lond). 2024; 86(8):4684-4694.

PMID: 39118763 PMC: 11305796. DOI: 10.1097/MS9.0000000000002107.


Tezepelumab: patient selection and place in therapy in severe asthma.

Menzella F, Munari S, Corsi L, Tonin S, Cestaro W, Ballarin A J Int Med Res. 2024; 52(4):3000605241246740.

PMID: 38676539 PMC: 11056094. DOI: 10.1177/03000605241246740.


TSLP in DRG neurons causes the development of neuropathic pain through T cells.

Ino Y, Maruyama M, Shimizu M, Morita R, Sakamoto A, Suzuki H J Neuroinflammation. 2023; 20(1):200.

PMID: 37660072 PMC: 10474733. DOI: 10.1186/s12974-023-02882-y.


TSLP bronchoalveolar lavage levels at baseline are linked to clinical disease severity and reduced lung function in children with asthma.

Chorvinsky E, Nino G, Salka K, Gaviria S, Gutierrez M, Pillai D Front Pediatr. 2022; 10:971073.

PMID: 36245744 PMC: 9557150. DOI: 10.3389/fped.2022.971073.


Targeting TSLP in Asthma.

Parnes J, Molfino N, Colice G, Martin U, Corren J, Menzies-Gow A J Asthma Allergy. 2022; 15:749-765.

PMID: 35685846 PMC: 9172920. DOI: 10.2147/JAA.S275039.


References
1.
Soumelis V, Reche P, Kanzler H, Yuan W, Edward G, Homey B . Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol. 2002; 3(7):673-80. DOI: 10.1038/ni805. View

2.
Venkayya R, Lam M, Willkom M, Grunig G, Corry D, Erle D . The Th2 lymphocyte products IL-4 and IL-13 rapidly induce airway hyperresponsiveness through direct effects on resident airway cells. Am J Respir Cell Mol Biol. 2002; 26(2):202-8. DOI: 10.1165/ajrcmb.26.2.4600. View

3.
Pope S, Brandt E, Mishra A, Hogan S, Zimmermann N, Matthaei K . IL-13 induces eosinophil recruitment into the lung by an IL-5- and eotaxin-dependent mechanism. J Allergy Clin Immunol. 2001; 108(4):594-601. DOI: 10.1067/mai.2001.118600. View

4.
Elias J, Zhu Z, Chupp G, Homer R . Airway remodeling in asthma. J Clin Invest. 1999; 104(8):1001-6. PMC: 408860. DOI: 10.1172/JCI8124. View

5.
Burrows B, Martinez F, Halonen M, BARBEE R, Cline M . Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med. 1989; 320(5):271-7. DOI: 10.1056/NEJM198902023200502. View